FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer

Alec Kacew; Randy F. Sweis; Randy F. Sweis; Randy F. Sweis

doi:10.3389/fimmu.2020.575258

Frontiers in Immunology (Nov 2020)

FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer

Alec Kacew,
Randy F. Sweis,
Randy F. Sweis,
Randy F. Sweis

Affiliations

Alec Kacew: Section of Hematology and Oncology, Department of Medicine, The University of Chicago, Chicago, IL, United States
Randy F. Sweis: Section of Hematology and Oncology, Department of Medicine, The University of Chicago, Chicago, IL, United States
Randy F. Sweis: Committee on Immunology, The University of Chicago, Chicago, IL, United States
Randy F. Sweis: Comprehensive Cancer Center, The University of Chicago, Chicago, IL, United States

DOI: https://doi.org/10.3389/fimmu.2020.575258
Journal volume & issue: Vol. 11

Abstract

Read online

FGFR3 is a prognostic and predictive marker and is a validated therapeutic target in urothelial bladder cancer. Its utility as a marker and target in the context of immunotherapy is incompletely understood. We review the role of FGFR3 in bladder cancer and discuss preclinical and clinical clues of its effectiveness as a patient selection factor and therapeutic target in the era of immunotherapy.

Published in Frontiers in Immunology

ISSN: 1664-3224 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: http://journal.frontiersin.org/journal/immunology

About the journal

Abstract

Keywords